| Literature DB >> 18671762 |
David Mitchell1, Lakshmi Paniker, Guillermo Sanchez, Zsolt Bella, Edina Garaczi, Marta Szell, Qutayba Hamid, Lajos Kemeny, Andrea Koreck.
Abstract
Ultraviolet radiation (UVR) phototherapy is a promising new treatment for inflammatory airway diseases. However, the potential carcinogenic risks associated with this treatment are not well understood. UV-specific DNA photoproducts were used as biomarkers to address this issue. Radioimmunoassay was used to quantify cyclobutane pyrimidine dimers (CPDs) and (6-4) photoproducts in DNA purified from two milieus: nasal mucosa samples from subjects exposed to intranasal phototherapy and human airway (EpiAirway) and human skin (EpiDerm) tissue models. Immunohistochemistry was used to detect CPD formation and persistence in human nasal biopsies and human tissue models. In subjects exposed to broadband ultraviolet radiation, DNA damage frequencies were determined prior to as well as immediately after treatment and at increasing times post-treatment. We observed significant levels of DNA damage immediately after treatment and efficient removal of the damage within a few days. No residual damage was observed in human subjects exposed to multiple UVB treatments several weeks after the last treatment. To better understand the molecular response of the nasal epithelium to DNA damage, parallel experiments were conducted in EpiAirway and EpiDerm model systems. Repair rates in these two tissues were very similar and comparable to that observed in human skin. The data suggest that the UV-induced DNA damage response of respiratory epithelia is very similar to that of the human epidermis and that nasal mucosa is able to efficiently repair UVB induced DNA damage.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18671762 PMCID: PMC3837592 DOI: 10.1111/j.1582-4934.2008.00442.x
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Fig 1Formation and resolution of DNA damage in human nasal epithelia from patients with seasonal allergic rhinitis receiving a single treatment of rhinophototherapy (RPT). Sample nasal epithelial tissue was collected from RPT patients that had received no RPT (-UV), immediately after the RPT treatment (T0) and at 24 (T24), 48 (T48) and 72 (T72) hrs after exposure. Cyclobutane dimers (grey bars) and (6–4) photoproducts (black bars) were determined using radioimmunoassay. Standard deviations were calculated from 4 data points from the RIAs of DNA extracted from tissue from various patients at different time points; including 30 patients prior to treatment, 30 immediately after treatment (T0) and 10 patients at T24, T48 and T72. Of the 30 original patients, the same patients were not necessarily available for tissue collection at all of the various time points.
Fig 2Long-term resolution of DNA damage in human nasal epithelia from patients receiving a 3-week course of rhinophototherapy for the treatment of seasonal allergies. Patients received either RPT (B) or a placebo treatment containing visible light with no UV radiation (A). Sample nasal epithelial tissue was collected either prior to treatment (-UV) or immediately after the 9th treatment (T0) and then at 1 week (T1) and 4 week (T4) intervals after the final treatment. The standard deviations were calculated from 4 data points from the RIAs of DNA extracted from tissues from 13 placebo and 13 treated patients.
Fig 3Immunohistochemical analysis of cyclobutane pyrimidine dimers in nasal epithelial tissues from patients subsequent to treatment with rhinophototherapy. Monoclonal antibodies specific for CPDs were used to visualize DNA damage in the nasal epithelium of patients 2 months after the final exposure to a RPT treatment for seasonal allergies (i.e. 9 treatments over a 3-week period). Tissue sections are shown for RPT-treated patients (C), sham-treated (visible light only) patients (B) and a positive control of UV irradiated 3D reconstructed normal human respiratory epithelium (EpiAirway) (A).
Fig 4DNA damage distribution in 3D reconstructed normal human respiratory epithelia (EpiAirway) exposed to different light sources. Immunohistochemistry using monoclonal antibodies specific for CPDs is shown immediately after irradiation with a broad-band UVC/UVB lamp used for RPT (Allux Medical) (C), a narrow-band Philips TL01 UVB lamp (B), a narrow-band UVC germicidal lamp (A) and the broadband UVC/UVB lamp shown in Panel A from which the UVB component had been removed (D).
Fig 5Nucleotide excision repair kinetics in 3D reconstructed normal human nasal epithelial and epidermal tissues. CPD and (6–4)PD repair are shown in EpiDerm (•–•) and EpiAirway (○–○) artificial tissues. The upper panels show the frequencies of CPDs (A) and (6–4)PDs (B) at increasing times post-irradiation as lesions per megabase DNA. Directly below each panel the frequencies have been normalized to the amount of damage measured at T0 and are expressed as the percentage of CPDs (C) and (6–4)PDs (D) remaining at increasing times post-irradiation with a single sublethal dose of UVB. Exponential decay curves for each data set are shown. Standard errors of the mean were calculated from standard deviations using a total of 8 data points from duplicate tissues.